





## The Board





Thérèse Esperdy Chair



Stefan Bomhard
Chief Executive Officer



Lukas Paravicini Chief Financial Officer



Sue Clark
Senior Independent
Non-Executive Director
and Remuneration
Committee Chair



Diane de Saint Victor Non-Executive Director



Ngozi Edozien Non-Executive Director



Alan Johnson
Non-Executive Director



Bob Kunze-Concewitz
Non-Executive Director



Simon Langelier
Non-Executive Director



Steven Stanbrook
Non-Executive Director



Jon Stanton
Non-Executive Director
and Audit Committee
Chair



John Downing Company Secretary

# **Board Engagement**





















# 2021 Highlights



#### OUR TRANSFORMATION TO DELIVER OUR FULL POTENTIAL

WIDER PORTFOLIO
Greater focus delivering
stronger performance




#### **PRIORITY MARKETS**

Targeted investments to stabilise market share



#### **CONSUMER**

New consumer office providing key insights



#### NGP

Targeted trials launched in line with plans

**✓** NEW WAYS OF WORKING

Simplified structure delivering focus and efficiencies



#### **PERFORMANCE**

Rigorous performance focus with new leadership

# Strengthened Leadership Team







Stefan Bomhard Chief Executive Officer Appointed: July 2020



Lukas Paravicini Chief Financial Officer Appointed: May 2021



Joerg Biebernick
President,
Europe Region
Joined: Nov 2017



Kim Reed
President and CEO,
Americas Region
Joined: June 2019



Paola Pocci President, Africa, Asia & Australasia Region Joined: Sept 2021



Murray McGowan Chief Strategy & Development Officer Joined: July 2020



Alison Clarke
Chief People & Culture
Officer
Joined: Sept 2020



Anindya Dasgupta
Chief Consumer
Officer
Joined: May 2021





Javier Huerta
Chief Supply Chain
Officer
Joined: Feb 2021

# Improving Share Trajectory in Priority Markets



SHARPER FOCUS BEGINS TO ARREST LONG-TERM SHARE DECLINES






## Successful Year of Delivery



#### A RESILIENT TOBACCO PERFORMANCE AND STRONG CASH FLOW

**TOBACCO NET REVENUE\*** 



**TOBACCO & NGP AOP\*** 



**ADJUSTED EPS\*** 



FREE CASH FLOW

£1.5bn

**NET DEBT TO EBITDA** 



to 2.2x (includes 0.1x FX benefit)

RETURN ON INVESTED CAPITAL



to 16.5%

## A Clear Five-Year Plan With Two Phases



#### GOOD PROGRESS IMPLEMENTING PHASE ONE OF OUR STRATEGY

#### **FY21 TO FY22**

#### Phase One - Strengthening

# Strategic focus

- Increased investment in operational growth drivers
- New ways of working to deliver efficiencies
- Implement operational excellence improvements

#### **FY23 TO FY25**

#### Phase Two – Improving Returns

- Investment and operational improvements enhance financial delivery
- Refine investment to consolidate delivery
- Leveraging efficiency benefits

# Net revenue

Gradually improving trajectory with 5-year CAGR of 1-2%


# Adjusted operating profit

 FY22 – Flat on FY21 (excluding non-repeat of net £40m US state litigation settlement) with no margin reset necessary

- Improving profit growth
- 3-year mid-single digit CAGR

## New Purpose and Vision

CREATING A COMMON HIGH-PERFORMANCE CULTURE FOR IMPERIAL BRANDS





"Forging a path to a healthier future for moments of relaxation and pleasure"




### **OUR VISION**

"To build a strong challenger business powered by responsibility, focus and choice"

## ESG: Foundations for a Responsible Business



OUR PURPOSE AND VISION DEFINE OUR ESG PRIORITIES



21

#### **PROGRESS**

- Launched NGP heated tobacco and vapour trials
- Commitment to net zero by 2040
- Step change in Board and ELT diversity
- Strengthened team with new ESG
   Director and Board committee

**22** 

#### **PRIORITIES**

- Conclude refresh of ESG strategy and priorities
- ESG Materiality Assessment and Stakeholder Engagement
- On track for Task Force on Climaterelated Disclosures (TCFD)





## 2022 Will Enhance Our Investment Case



CLEAR ACTIONS TO IMPROVE PERFORMANCE AND RETURNS

#### **FY22 PRIORITIES**



Increased investment in priority markets



INVESTMENT CASE

Revitalised tobacco business driving strong cash returns



NGP targeted trials



A disciplined NGP business providing options for potential harm reduction and growth



Embedding new ways of working



Self-help initiatives deliver operational improvement and strengthen performance



Continued focus on cash delivery



Strong sustainable cash flow generated from a highquality portfolio



Disciplined capital allocation



Progressive dividend supplemented by capital returns at the appropriate time

